FDA Morale Improvement Will Be A Priority, Von Eschenbach Testifies
This article was originally published in The Gray Sheet
Executive Summary
Acting FDA Commissioner Andrew von Eschenbach stressed his commitment to improving agency morale during his confirmation hearing
You may also be interested in...
Von Eschenbach Nomination Still Stalled After Some Movement On Plan B
Senators Hilary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) will maintain their hold on Andrew von Eschenbach's nomination to head FDA, despite what von Eschenbach calls an "important decision" regarding Barr Laboratories' application to offer its Plan B emergency contraceptive over the counter (OTC)
FDA Scientists Fear Retaliation For Conveying Health Risks, Survey Finds
FDA scientists fear retaliation for expressing health concerns to the public, according to results of a Union of Concerned Scientists survey released July 20
Increasing Number Of Appeals Add To Unresolved Issues For Ombudsman
CDRH's ombudsman says more manufacturer appeals of decisions made by the device center's evaluation office are causing longer resolution times for many complaints and disputes filed with the center